
Mirvetuximab Soravtansine Sustains OS Benefit in FRα+ PROC
Mirvetuximab soravtansine-gynx (Elahere) continued to showcase superior overall survival (OS) and maintained other clinical benefits over investigator’s choice of chemotherapy (ICC) in patients with folate receptor α (FRα)–positive, platinum-resistant …